PSI Journal Club: Limitations and Challenges with Mixed Model Repeated Measures (MMRM) Analysis
Moses Mwangi and Florian Lasch present their recent work on MMRM, with discussion lead by Geert Molenberghs.
3 years
When I was employed as a Statistician in AstraZeneca 3 years ago, I didn’t know much about the pharmaceutical industry. I had just obtained my Master’s degree in Applied Statistics from Örebro University (Sweden) and my previous work experience in statistics was from part-time jobs in the field of economics, medicine and social studies. During my first year in AstraZeneca, I was mainly doing exploratory work to inform study design and assess the robustness of results from finished studies. This helped me to get familiar with the industry processes and what stands behind the clinical programmes design, regulatory submissions and commercialisation. Gradually, I gained more independence and responsibilities in designing studies, deciding on analysis approaches and communicating with external partners. I was promoted to a Senior Statistician after 2 years of working, which is my current role.
I would typically have 1-3 meetings a day with colleagues such as physicians, safety experts, data management experts, statistical programmers, medical writers and other study and project team members as well as external vendors and partners.
I would review project documents or outputs from vendors or team members or would work on drafting and finalizing internal documents or outputs. I would produce analyses for internal use or would do literature research for incorporating the best analyses approach in our study design.
I am doing something different every day and constantly developing different technical and soft skills. There are so many different sub-areas that a statistician can work on within a pharmaceutical company that it is easy to find something that you enjoy or explore other areas if you want to try something new. I also like the sense of importance in the work my colleagues and I do and cannot help but feel proud for contributing to the development of new and better medicines for patients.
Moses Mwangi and Florian Lasch present their recent work on MMRM, with discussion lead by Geert Molenberghs.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Talks from speakers will cover an introduction to HTA and indirect comparisons for value assessment before focusing in more specifically on topics related to the use of indirect treatment comparisons for patient access.
Talks from the speakers will cover the use of R in a programming community, submitted to regulators using R, and also programming beyond R in C++ and Julia.
This course is aimed at clinical trial statisticians who are new to or with limited experience of machine learning. Attendees will learn about a range of topics in machine learning, including practical sessions in R.
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.